This Hot Biotech Blasts Off On Patent Breakthroughs

$IMLFF $IN.C On watch for another BIG move and stays on High Trading Alert


Shares of InMed Pharmaceuticals Inc. (OTCQB:IMLFF CSE: IN.c) shot to a record high of $0.86 out of the gate this week, trading up over 127% over the past 45 days. Due in part to this emerging biotech reporting 2 successful patent filings for its Biosynthesis and Pain Programs and trial results for one of its pain drugs. Importantly, InMed recently announced pre-clinical results in the development of INM-405 for the treatment of pain; succesfully demonstrating their Bioinformatics, Biosynthesis and Drug Development IP

InMed filed two provisional patent applications: the first pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature and another for for INM-405 with unique compositions for cannabinoid-based topical therapies for the treatment of pain. These are important steps in protecting the Company's intellectual and commercial property. The foundation of the INM-405  patent is for the development of non-THC cannabinoids and their ability to modulate pain. The patent cites a range of cannabinoids, alone or in combination, applied topically to treat various types of pain - muscle, nerve, arthritis-induced joint pain, etc.

The $58.6 billion global market for pain management drugs is on track to hit upwards of $77.1 billion by 2023 on a four percent CAGR , and InMed’s (OTCQB: IMLFF CSE: IN.c)  pre-clinical pain results are important developments to combat dangerous opioid drug side effects. Hoping to shift market focus to cannabis in the treatment of  chronic pain.

$IMLFF is holding breakout levels and looks very close to another, charting towards the $1.00+ barrier as you can see with the positive trendline.




Given IMLFF's brow-raising 127.5% - 45 day gain, it's possible shareholders maybe waiting for the $1.00 breakout. Whatever the motive, Biopharmacuetical companies may offer important developments in the need to find alternatives to treat chronic and severe pain that are non-addictive and have limited side effects.





DISCLAIMER: The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. The Seed Investor is an independent subscriber/membersonly news website. This online report and document is a solicitation for membership in the The Seed Investor service. The Seed Investor did not receive any Direct compensation with respect to the writing of this online report and document. This stock was chosen to be profiled after The Seed Investor completed due diligence on the stock. The Seed Investor expects to generate new membership revenue, the amount of which is unknown at this time, to its website through the distribution of this online report and document. This constitutes a conflict of interest as to TSI’s ability to remain objective in its communication regarding the subject company. Analysts, principals, associates and employees of TSI do not own or trade equities under coverage. For detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934. TSI is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement. Information contained herein contains forward looking statements and is subject to significant risks and uncertainties, which will affect the results. The opinions contained herein reflect our current judgment and are subject to change without notice. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov and the National Association of Securities Dealers (NASD) at http://www.nasd.com. The NASD has published information on how to invest carefully. Readers can review all public filings by companies at the SEC’s EDGAR page.

Third Party/Agency Disclaimer: Content of this message is published by The Seed Investor and sent to select our mailing list through various marketing media to provide readers with information on selected publicly-traded companies. Theseedinvestor.com newsletter (hereafter called “TSI”) is an information and marketing firm wholly owned by Dynamic Wealth Publishing, LLC and is not a financial analyst, investment adviser or broker/dealer. TSI is in the business of marketing and advertising companies to generate exposure of them by sending alerts to our subscribers for monetary compensation. Dynamic Wealth Publishing, LLC has been compensated thirty six thousand dollars from IR Media Services Inc. (a non-controlling third party) for advertising and promotional services.

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimer. This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. (Read full disclaimer)